0 Item(s)
2023 Webinar: Let's Talk About Drugs: New Trials and Pharmacotherapies in Cardiac Rehab
This webinar will provide updates on new major clinical trials and the evolution of medication treatments in cardiovascular prevention. It will also discuss anti-platelet and anti-thrombotic combinations for CAD and describe emerging approaches to lipid, BP and DM management to modify CV risk.
Credit Information
1.0
Description
Presented by: Paul Oh, MD, MSc, FRCPC, FACP, FAACVPR
Disclosures - Research support - Apple; Advisory Board - Lilly, Novartis
Disclosures - Research support - Apple; Advisory Board - Lilly, Novartis
Description: This webinar will provide updates on new major clinical trials and the evolution of medication treatments in cardiovascular prevention. It will also discuss anti-platelet and anti-thrombotic combinations for CAD and describe emerging approaches to lipid, BP and DM management to modify CV risk.
Learning Objectives:
- Discuss 3 reasons why ASA may be insufficient for platelet inhibition.
- Describe 2 mechanisms of modifying PCSK9
- Identify at least 2 physiologic reasons that beta-blockers and renin-angiotensin systems inhibitors reduce MI risk
- State 2 types of diabetes medications that have cardioprotective effects
- List 4 old drugs and 4 new drugs that may be part of the prevention "cocktail."
Viewing Window: 60 days from date of purchase
Courses in package:
| Title | Credit(s) | |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| 4 |